ATE253360T1 - Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol - Google Patents

Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol

Info

Publication number
ATE253360T1
ATE253360T1 AT98947501T AT98947501T ATE253360T1 AT E253360 T1 ATE253360 T1 AT E253360T1 AT 98947501 T AT98947501 T AT 98947501T AT 98947501 T AT98947501 T AT 98947501T AT E253360 T1 ATE253360 T1 AT E253360T1
Authority
AT
Austria
Prior art keywords
taxol
improve
oral bioavailability
acridine derivatives
derivatives
Prior art date
Application number
AT98947501T
Other languages
English (en)
Inventor
Jan H M Schellens
Plesmanlaan
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE253360T1 publication Critical patent/ATE253360T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
AT98947501T 1997-09-05 1998-09-03 Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol ATE253360T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9718903.9A GB9718903D0 (en) 1997-09-05 1997-09-05 Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
PCT/EP1998/005557 WO1999012570A2 (en) 1997-09-05 1998-09-03 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents

Publications (1)

Publication Number Publication Date
ATE253360T1 true ATE253360T1 (de) 2003-11-15

Family

ID=10818634

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98947501T ATE253360T1 (de) 1997-09-05 1998-09-03 Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol

Country Status (15)

Country Link
US (2) US6469022B1 (de)
EP (1) EP1009436B1 (de)
JP (2) JP4516688B2 (de)
KR (1) KR100579030B1 (de)
AT (1) ATE253360T1 (de)
AU (1) AU751085B2 (de)
BR (1) BR9812179A (de)
CA (1) CA2302568C (de)
DE (1) DE69819525T2 (de)
DK (1) DK1009436T3 (de)
ES (1) ES2210823T3 (de)
GB (1) GB9718903D0 (de)
PT (1) PT1009436E (de)
TR (1) TR200000586T2 (de)
WO (1) WO1999012570A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
CN1261275A (zh) * 1997-05-27 2000-07-26 巴克·诺顿药物有限公司 给予病人口服紫杉烷类药物的方法和组合物
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
DE60030283T2 (de) * 1999-05-17 2007-09-20 Cancer Research Ventures Ltd. Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
EP1479382A1 (de) * 1999-06-18 2004-11-24 IVAX Research, Inc. Taxane enthaltende orale Pharmazeutische Zusammensetzungen sowie Behandlungsverfahren unter deren Verwendung
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
ES2622471T5 (es) 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
WO2005099680A2 (en) * 2004-04-12 2005-10-27 United Therapeutics, Inc. Use of treprostinil to treat neuropathic diabetic foot ulcers
US8518022B2 (en) 2004-08-27 2013-08-27 Medimetrics Personalized Drug Delivery, Inc. Electronically and remotely controlled pill and system for delivering at least one medicament
US20090234331A1 (en) * 2004-11-29 2009-09-17 Koninklijke Philips Electronics, N.V. Electronically controlled pill and system having at least one sensor for delivering at least one medicament
US20100331827A1 (en) * 2008-02-18 2010-12-30 Koninklijke Philips Electronics N.V. Administration of drugs to a patient
WO2009122323A1 (en) * 2008-03-31 2009-10-08 Koninklijke Philips Electronics N.V. Method of preparing a swallowable capsule comprising a sensor
JP5500600B2 (ja) 2008-06-19 2014-05-21 コーニンクレッカ フィリップス エヌ ヴェ 湿った環境における粉状薬物の供給のためのデバイス
RU2011102576A (ru) * 2008-06-25 2012-07-27 Конинклейке Филипс Электроникс Н.В. (Nl) Электронная таблетка, содержащая множество емкостей с лекарственным средствами
JP5497176B2 (ja) 2009-08-12 2014-05-21 コーニンクレッカ フィリップス エヌ ヴェ 圧縮可能な薬品貯槽を備える薬品送出装置
JP2016517410A (ja) 2013-03-14 2016-06-16 ユナイテッド セラピューティクス コーポレイション トレプロスチニルの固体形態
WO2015035218A1 (en) * 2013-09-05 2015-03-12 Howard University Method of increasing the bioavailability of an hiv drug
TWI838700B (zh) * 2015-09-30 2024-04-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100220538B1 (ko) 1991-01-11 1999-09-15 뮈쉘 쥐르밀 아크리딘 유도체
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CN1261275A (zh) * 1997-05-27 2000-07-26 巴克·诺顿药物有限公司 给予病人口服紫杉烷类药物的方法和组合物
GB9718903D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE60030283T2 (de) * 1999-05-17 2007-09-20 Cancer Research Ventures Ltd. Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen

Also Published As

Publication number Publication date
KR100579030B1 (ko) 2006-05-12
US6803373B2 (en) 2004-10-12
DK1009436T3 (da) 2004-03-08
CA2302568C (en) 2010-06-22
AU751085B2 (en) 2002-08-08
EP1009436A2 (de) 2000-06-21
US6469022B1 (en) 2002-10-22
KR20010023670A (ko) 2001-03-26
PT1009436E (pt) 2004-03-31
BR9812179A (pt) 2000-07-18
DE69819525D1 (de) 2003-12-11
AU9439498A (en) 1999-03-29
WO1999012570A3 (en) 1999-08-19
US20030013731A1 (en) 2003-01-16
CA2302568A1 (en) 1999-03-18
JP2001515872A (ja) 2001-09-25
TR200000586T2 (tr) 2000-09-21
ES2210823T3 (es) 2004-07-01
GB9718903D0 (en) 1997-11-12
WO1999012570A2 (en) 1999-03-18
DE69819525T2 (de) 2004-09-23
EP1009436B1 (de) 2003-11-05
JP2010059185A (ja) 2010-03-18
JP4516688B2 (ja) 2010-08-04

Similar Documents

Publication Publication Date Title
ATE253360T1 (de) Acridine derivate zur verbesserung der oralen bioverfügbarkeit von taxol
PT1109812E (pt) Pirrolobenzodiazepinas
DE60032780D1 (de) Tetrahydroquinolin-derivate
ATE263147T1 (de) Derivate von aryloxyarylsulfonylamino hydroxyaminsäuren
CY1109276T1 (el) Φωσφονοκεφεμικα παραγωγα, διαδικασια για την παρασκευη τους, και χρηση αυτων
DE122004000018I2 (de) 4"-substitutierte-9-deoxo-9a-aza-9a-homoerythromycin a derivate
TR200101961T2 (tr) 1,2-halkalı kinolin türevleri
DE69839131D1 (de) Arylkondensierte azapolycyclische derivate
DK0977741T3 (da) Substituerede phenylderivater, deres fremstilling og anvendelse
PT1000048E (pt) Derivados substituidos do 1,2,3,4-tetrahidronaftaleno
EP1191933A4 (de) Nasale verabreichung von apomorphin
FI963169A0 (fi) Enkefalinaasin ja ACE:n inhibittoreina käyttökelpoisia uusia merkaptoasetyyliamido-1,3,4,5-tetrahydrobents/c/-atsepin-3-onidisulfidijohdannaisia
ATE231149T1 (de) (1,8)-naphthyridinderivate derivate mit antiviraler wirkung
EP0976748A4 (de) Pyrrolidin-derivate die eine phospholipase-a2-hemmende wirkung haben
DE58904761D1 (de) Chirale derivate des 1,2 -difluorbenzols.
ATE126509T1 (de) Disäuren von diarylstyrylchinolin.
EP1029860A4 (de) Benzofuranderivate
IT1295933B1 (it) 2-(2'-idrossifenil)benzotriazoli e procedimento per la loro preparazione
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
DE69611758D1 (de) N-1-carbocylalkyl derivate von lsd
BR0114380A (pt) Derivados-1-aminobutan-3-ol-substituìdos
DE69908614D1 (de) Herstellung von n-substituierten-hydroxycycloalkylamin-derivaten
ATE254929T1 (de) Oralverabreichbare lösung von prucaloprid
NO20006350D0 (no) Derivater av 3-(2-okso-[1,3']bipyrrolidinyl-3-ylidenmetyl)- cephemer
SE9701438D0 (sv) A new process

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1009436

Country of ref document: EP